A Potential Peptide Therapeutic Derived from the Juxtamembrane Domain of the Epidermal Growth Factor Receptor

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Boran, Aislyn D W ^a   Seco, Joseph ^a   Jayaraman, Vinodh ^a   Jayaraman, Gomathi ^a   Zhao, Shan ^a   Reddy, Sushmitha ^a   Chen, Yibang ^a   Iyengar, Ravi ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; TE 64562; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; DIMERIZATION; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MICE; MICE, NUDE; PEPTIDES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TUMOR BURDEN; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84869222520     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049702     Document Type: Article

References (42)

1. Pines G, Kostler WJ, Yarden Y, (2010) Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett 584: 2699-2706.
2. Takeuchi K, Ito F, (2010) EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J 277: 316-326.
3. Wheeler DL, Dunn EF, Harari PM, (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7: 493-507.
4. Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, et al. (2006) Targeting the EGFR pathway for cancer therapy. Curr Med Chem 13: 3483-3492.
5. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, et al. (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304: 1812-1820.
6. Vakiani E, Solit DB, (2010) KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 223: 219-229.
7. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, et al. (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9: 962-972.
8. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
9. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
10. Aifa S, Aydin J, Nordvall G, Lundstrom I, Svensson SP, et al. (2005) A basic peptide within the juxtamembrane region is required for EGF receptor dimerization. Exp Cell Res 302: 108-114.
11. Macdonald-Obermann JL, Pike LJ, (2009) The intracellular juxtamembrane domain of the epidermal growth factor (EGF) receptor is responsible for the allosteric regulation of EGF binding. J Biol Chem 284: 13570-13576.
12. Thiel KW, Carpenter G, (2007) Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation. Proc Natl Acad Sci U S A 104: 19238-19243.
13. Jura N, Endres NF, Engel K, Deindl S, Das R, et al. (2009) Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 137: 1293-1307.
14. Martin-Nieto J, Villalobo A, (1998) The human epidermal growth factor receptor contains a juxtamembrane calmodulin-binding site. Biochemistry 37: 227-236.
15. McLaughlin S, Smith SO, Hayman MJ, Murray D, (2005) An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family. J Gen Physiol 126: 41-53.
16. Michailidis IE, Rusinova R, Georgakopoulos A, Chen Y, Iyengar R, et al. (2011) Phosphatidylinositol-4,5-bisphosphate regulates epidermal growth factor receptor activation. Pflugers Arch 461: 387-397.
17. Sato T, Pallavi P, Golebiewska U, McLaughlin S, Smith SO, (2006) Structure of the membrane reconstituted transmembrane-juxtamembrane peptide EGFR(622-660) and its interaction with Ca2+/calmodulin. Biochemistry 45: 12704-12714.
18. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, et al. (2009) The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 34: 641-651.
19. Burgess AW, (2008) EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 26: 263-274.
20. Bennasroune A, Fickova M, Gardin A, Dirrig-Grosch S, Aunis D, et al. (2004) Transmembrane peptides as inhibitors of ErbB receptor signaling. Mol Biol Cell 15: 3464-3474.
21. Lofts FJ, Hurst HC, Sternberg MJ, Gullick WJ, (1993) Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. Oncogene 8: 2813-2820.
22. Zwang Y, Yarden Y, (2006) p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J 25: 4195-4206.
23. Adachi S, Natsume H, Yamauchi J, Matsushima-Nishiwaki R, Joe AK, et al. (2009) p38 MAP kinase controls EGF receptor downregulation via phosphorylation at Ser1046/1047. Cancer Lett 277: 108-113.
24. Watanabe T, Otsu K, Takeda T, Yamaguchi O, Hikoso S, et al. (2005) Apoptosis signal-regulating kinase 1 is involved not only in apoptosis but also in non-apoptotic cardiomyocyte death. Biochem Biophys Res Commun 333: 562-567.
25. deFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL, (2000) Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 87: 487-498.
26. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K, (2003) Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 278: 35109-35114.
27. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, et al. (2007) Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 40: 580-594.
28. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, et al. (2010) An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 70: 2485-2494.
29. Janmaat ML, Rodriguez JA, Jimeno J, Kruyt FA, Giaccone G, (2005) Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol Pharmacol 68: 502-510.
30. Schaefer KL, Brachwitz K, Braun Y, Diallo R, Wai DH, et al. (2006) Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue. Neoplasia 8: 613-622.
31. Verneris MR, Arshi A, Edinger M, Kornacker M, Natkunam Y, et al. (2005) Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res 11: 4561-4570.
32. Pruss RM, Herschman HR, (1977) Variants of 3T3 cells lacking mitogenic response to epidermal growth factor. Proc Natl Acad Sci U S A 74: 3918-3921.
33. Wang LM, Kuo A, Alimandi M, Veri MC, Lee CC, et al. (1998) ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. Proc Natl Acad Sci U S A 95: 6809-6814.
34. Giovannini MG, Blitzer RD, Wong T, Asoma K, Tsokas P, et al. (2001) Mitogen-activated protein kinase regulates early phosphorylation and delayed expression of Ca2+/calmodulin-dependent protein kinase II in long-term potentiation. J Neurosci 21: 7053-7062.
35. Ronai Z, (1999) Deciphering the mammalian stress response- a stressful task. Oncogene 18: 6084-6086.
36. Rosette C, Karin M, (1996) Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 274: 1194-1197.
37. Chen P, Xie H, Sekar MC, Gupta K, Wells A, (1994) Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol 127: 847-857.
38. Human Mammary Epithelial Cell (HMEC) Bank Website. Available: http://hmec.lbl.gov/mindex.html. Accessed 2012 Oct 17.
39. Garbe JC, Holst CR, Bassett E, Tlsty T, Stampfer MR, (2007) Inactivation of p53 function in cultured human mammary epithelial cells turns the telomere-length dependent senescence barrier from agonescence into crisis. Cell Cycle 6: 1927-1936.
40. Hammond SL, Ham RG, Stampfer MR, (1984) Serum-free growth of human mammary epithelial cells: rapid clonal growth in defined medium and extended serial passage with pituitary extract. Proc Natl Acad Sci U S A 81: 5435-5439.
41. Stampfer MR, (1982) Cholera toxin stimulation of human mammary epithelial cells in culture. In Vitro 18: 531-537.
42. Stampfer MR, Yaswen P, (2003) Human epithelial cell immortalization as a step in carcinogenesis. Cancer Lett 194: 199-208.